136 related articles for article (PubMed ID: 15100376)
1. Pharmacoepidemiology of anemia in kidney transplant recipients.
Winkelmayer WC; Kewalramani R; Rutstein M; Gabardi S; Vonvisger T; Chandraker A
J Am Soc Nephrol; 2004 May; 15(5):1347-52. PubMed ID: 15100376
[TBL] [Abstract][Full Text] [Related]
2. Anemia in pediatric renal transplant recipients.
Kausman JY; Powell HR; Jones CL
Pediatr Nephrol; 2004 May; 19(5):526-30. PubMed ID: 15007719
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
[TBL] [Abstract][Full Text] [Related]
5. Posttransplantation anemia at 12 months in kidney recipients treated with mycophenolate mofetil: risk factors and implications for mortality.
Imoagene-Oyedeji AE; Rosas SE; Doyle AM; Goral S; Bloom RD
J Am Soc Nephrol; 2006 Nov; 17(11):3240-7. PubMed ID: 17035616
[TBL] [Abstract][Full Text] [Related]
6. Late evolution of kidney transplants in elderly donors and recipients receiving initial immunosuppressant treatment with daclizumab, mycophenolate mofetil, and delayed introduction of tacrolimus.
González-Roncero FM; Gentil-Govantes MÁ; González-Molina M; Rivero M; Cantarell C; Alarcón A; Franco A; Sánchez-Plumed J; Lampreabe I; Lauzurica R; González E; Romero R; Ruiz-San Millán JC; Osuna A
Nefrologia; 2012 Jul; 32(4):446-54. PubMed ID: 22806279
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetil.
Rush DN; Cockfield SM; Nickerson PW; Arlen DJ; Boucher A; Busque S; Girardin CE; Knoll GA; Lachance JG; Landsberg DN; Shapiro RJ; Shoker A; Yilmaz S
Transplantation; 2009 Oct; 88(7):897-903. PubMed ID: 19935461
[TBL] [Abstract][Full Text] [Related]
9. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
[TBL] [Abstract][Full Text] [Related]
10. Anemia in kidney transplants without erythropoietic agents: levels of erythropoietin and iron parameters.
Florit EA; Hadad F; Rodriguez Cubillo B; De la Flor JC; Valga F; Perez Flores I; Calvo Romero N; Valero San Cecilio R; Barrientos Guzman A; Sanchez Fructuoso A
Transplant Proc; 2012 Nov; 44(9):2590-2. PubMed ID: 23146464
[TBL] [Abstract][Full Text] [Related]
11. Treatment of anemia with erythropoietin-stimulating agents in kidney transplant recipients and chronic kidney disease-another drawback of immunosuppression?
Malyszko J; Glowinska I; Mysliwiec M
Transplant Proc; 2012 Dec; 44(10):3013-6. PubMed ID: 23195016
[TBL] [Abstract][Full Text] [Related]
12. Post-transplant anemia and associated risk factors: the impact of steroid-free therapy.
Oliveira CM; Timbó PS; Pinheiro SR; Leite JG; Timbó LS; Esmeraldo RM
Sao Paulo Med J; 2013; 131(6):369-76. PubMed ID: 24346775
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
[TBL] [Abstract][Full Text] [Related]
14. Preserved insulin secretion and kidney function in recipients with functional pancreas grafts 1 year after transplantation: a single-center prospective observational study.
Nordheim E; Birkeland KI; Åsberg A; Hartmann A; Horneland R; Jenssen T
Eur J Endocrinol; 2018 Oct; 179(4):251-259. PubMed ID: 30299895
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus, Mycophenolate Mofetil, and Low-Dose Steroids With or Without Interleukin-2 Receptor Antibody Induction Therapy: A Retrospective Cohort Analysis.
Schwarz C; Böhmig G; Steininger R; Unger L; Kristo I; Kozakowski N; Berlakovich GA; Soliman T; Mühlbacher F
Transplant Proc; 2015 Oct; 47(8):2446-9. PubMed ID: 26518948
[TBL] [Abstract][Full Text] [Related]
16. A Retrospective Study on Mycophenolic Acid Drug Interactions: Effect of Prednisone, Sirolimus, and Tacrolimus With MPA.
Alvarez-Elías AC; Yoo EC; Todorova EK; Singh RN; Filler G
Ther Drug Monit; 2017 Jun; 39(3):220-228. PubMed ID: 28437284
[TBL] [Abstract][Full Text] [Related]
17. Negative impact of one-year anemia on long-term patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil.
Kamar N; Rostaing L
Transplantation; 2008 Apr; 85(8):1120-4. PubMed ID: 18431231
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with tacrolimus and mycophenolate mofetil: effects of early and late minimization of mycophenolate mofetil after renal transplant.
Walker R; Thomas M; Goodman D; Campbell S; Chadban S;
Clin Transplant; 2008; 22(5):594-602. PubMed ID: 18459999
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors for anemia six and twelve months after orthotopic liver transplantation.
Guitard J; Ribes D; Kamar N; Muscari F; Lavayssière L; Suc B; Esposito L; Perron JM; Rostaing L
Transplantation; 2006 Jun; 81(11):1525-31. PubMed ID: 16770241
[TBL] [Abstract][Full Text] [Related]
20. Absence of the Effect of Pretransplant Body Mass Index on Post Kidney Transplant Outcomes.
Tremblay S; Kaiser TE; Alloway RR; Woodle ES; Diwan TS
Prog Transplant; 2016 Jun; 26(2):183-90. PubMed ID: 27207408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
